News | May 16, 2025
Shelter Pharma launches three new products
Shelter Pharma Limited is set to capitalize on the growing demand for natural health products in India
Shelter Pharma Limited is set to capitalize on the growing demand for natural health products in India
Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25
The CDMO upgrade represents a transformational step for Remedium Lifecare
Haloperidol Decanoate Injection indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy
Ideal for extreme dry skin and hyperkeratotic conditions such as psoriasis and ichthyosis, Ureaderm offers the next step in evidence-based, effective skin hydration
_256_384.jpg)
The company reported 30.1% jump in Q4 FY25 PAT at Rs. 1,222 crore
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
Tolvaptan Tablets are indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease
The Protect VL project was born out of a vision to reduce the environmental footprint of medical devices
Subscribe To Our Newsletter & Stay Updated
